Table 2.
Expression of EGFR, β-catenin, CEA, c-Myc and Ki-67 antibodies and their association with other clinical, biological, histopathological and genetic features of sporadic colorectal cancer patients (n = 51).
| Variable | EGFR | p | β-catenin | p | CEA | p | c-Myc | p | Ki-67 | p | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <35% | ≥35% | − | + | − | + | <10% | ≥10% | <50% | ≥50% | ||||||
| Age (years) | |||||||||||||||
| <72 | 21 (78) | 6 (22) | NS | 15 (55) | 12 (45) | NS | 5 (19) | 22 (81) | NS | 6 (22) | 21 (78) | NS | 20 (74) | 7 (26) | NS |
| ≥72 | 15 (65) | 8 (35) | 14 (61) | 9 (39) | 6 (26) | 17 (74) | 3 (17) | 18 (83) | 15 (65) | 8 (35) | |||||
| Gender | |||||||||||||||
| Male | 25 (68) | 12 (32) | NS | 23 (62) | 14 (38) | NS | 9 (24) | 28 (76) | NS | 7 (19) | 29 (81) | NS | 24 (65) | 13(35) | NS |
| Female | 11 (85) | 2 (15) | 6 (46) | 7 (54) | 2 (15) | 11 (85) | 2 (17) | 10 (83) | 11 (85) | 2(15) | |||||
| Site of primary tumor | |||||||||||||||
| Colon | 28 (76) | 9 (24) | NS | 22 (59) | 15 (41) | NS | 11 (30) | 26 (70) | 0.030 | 5 (14) | 31 (86) | NS | 25 (68) | 12 (32) | NS |
| Rectum | 8 (62) | 5 (38) | 7 (46) | 6 (54) | 0 (0) | 13 (100) | 4 (33) | 8 (67) | 10 (77) | 3 (23) | |||||
| Histopathological grade | |||||||||||||||
| Well differentiated | 24 (71) | 10 (39) | 20 (59) | 14 (41) | 7 (21) | 27 (79) | 7 (21) | 26 (79) | 21 (62) | 13 (38) | NS | ||||
| Moderately differentiated | 11 (79) | 3 (21) | NS | 8 (57) | 6 (43) | NS | 4 (29) | 10 (71) | NS | 2 (14) | 12 (86) | NS | 12 (86) | 2 (14) | |
| Poorly differentiated | 1 (50) | 1 (50) | 1 (50) | 1 (50) | 0 (0) | 2 (100) | 0 (0) | 1 (100) | 2 (100) | 0 (0) | |||||
| pT stage | |||||||||||||||
| T1-T2 | 8 (100) | 0 | NS | 3 (38) | 5 (62) | NS | 3 (38) | 5 (62) | 0.007 | 0 (0) | 8 (100) | NS | 5 (62) | 3 (38) | NS |
| T3-T4 | 28 (67) | 14 (33) | 16 (38) | 26 (62) | 8 (19) | 34 (81) | 9 (22) | 31 (88) | 30 (71) | 12 (29) | |||||
| Lymph node involvement | |||||||||||||||
| N0 | 30 (86) | 5 (14) | 0.001 | 21 (62) | 13 (38) | NS | 11 (44) | 24 (56) | 0.010 | 5 (15) | 28 (85) | NS | 24 (69) | 11 (31) | NS |
| N1/N2 | 6 (40) | 9 (60) | 8 (50) | 8 (50) | 0 (0) | 15 (100) | 4 (27) | 11 (73) | 11 (73) | 4 (27) | |||||
| Liver metastases at diagnosis | |||||||||||||||
| No | 29 (94) | 2 (6) | <0.001 | 19 (63) | 11 (37) | NS | 11 (35) | 20 (65) | 0.003 | 3 (10) | 26 (90) | NS | 19 (61) | 12 (39) | NS |
| Yes | 7 (37) | 12 (63) | 10 (50) | 10 (50) | 0 (0) | 19 (100) | 6 (32) | 13 (68) | 6 (31) | 13 (69) | |||||
| pTNM stage at diagnosis | |||||||||||||||
| I | 7 (100) | 0 | 2 (29) | 5 (71) | 3 (43) | 4 (57) | 0 (0) | 7 (100) | 4 (57) | 3 (43) | NS | ||||
| II | 19 (95) | 1 (5) | <0.001 | 15 (79) | 4 (21) | NS | 6 (30) | 14 (70) | 0.007 | 2 (11) | 16 (89) | 0.030 | 12 (30) | 18 (70) | |
| III | 3 (75) | 1 (25) | 2 (50) | 2 (50) | 2 (50) | 2 (50) | 1 (25) | 3(75) | 3 (75) | 1 (25) | |||||
| IV | 7 (37) | 12 (63) | 10 (50) | 10 (50) | 0 (0) | 19 (100) | 6 (31) | 13 (69) | 16 (84) | 3 (16) | |||||
| Tumor size | |||||||||||||||
| <4 cm | 8 (80) | 2 (20) | NS | 5 (50) | 5 (50) | NS | 0 (0) | 10 (100) | NS | 2 (20) | 8 (80) | NS | 9 (90) | 1 (10) | NS |
| ≥4 cm | 28 (70) | 12 (30) | 24 (60) | 16 (40) | 11 (28) | 29 (72) | 7 (18) | 31 (82) | 26 (65) | 14 (35) | |||||
| Microsatellite instability | |||||||||||||||
| No | 27 (66) | 14 (34) | NS | 20 (49) | 21 (51) | 0.007 | 4 (10) | 37 (90) | <0.001 | 9 (23) | 30 (77) | NS | 32 (78) | 9 (22) | 0.030 |
| Yes | 8 (100) | 0 | 8 (100) | 0 (0) | 8 (100) | 0 (0) | 0 (0) | 8 (100) | 3 (37) | 5 (63) | |||||
| KRAS mutation | |||||||||||||||
| No | 35 (78) | 10 (22) | 0.001 | 26 (58) | 19 (42) | NS | 11 (24) | 34 (76) | NS | 7 (16) | 36 (84) | NS | 31 (69) | 14 (31) | NS |
| Yes | 0 | 4 (100) | 3 (75) | 1 (25) | 0 (0) | 4 (100) | 2 (50) | 2 (50) | 3 (75) | 1 (25) | |||||
| NRAS mutation | |||||||||||||||
| No | 33 (75) | 11 (25) | NS | 18 (53) | 16 (47) | 0.010 | 10 (23) | 34 (77) | NS | 8 (19) | 34 (81) | NS | 30 (68) | 14 (32) | NS |
| Yes | 2 (50) | 2 (50) | 0 (0) | 4 (100) | 1 (25) | 3 (75) | 0 (0) | 4 (100) | 3 (75) | 1 (25) | |||||
| BRAF mutation | |||||||||||||||
| No | 31 (89) | 4 (11) | NS | 26 (58) | 19 (42) | NS | 8 (18) | 37 (82) | 0.008 | 8 (20) | 31 (80) | NS | 33 (73) | 12 (28) | 0.040 |
| Yes | 4 (100) | 0 | 1 (25) | 3 (75) | 3 (75) | 1 (25) | 1 (25) | 3 (75) | 1 (25) | 3 (75) | |||||
Results expressed as number of cases (percentage); CEA: carcinoembryogenic antigen; NS: no statistically significant differences found between groups (p > 0.05).